Mostrando 2 resultados de: 2
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial
ArticleAbstract: Background: Covert vascular disease of the brain manifests as infarcts, white matter hyperintensitiePalabras claves:Anticoagulant, Clinical trial, COGNITION, magnetic resonance imaging, prevention, silent infarctAutores:Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Cook-Bruns N., Dagenais G.R., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Ha J.W., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Wong G., Yuan F., Yusuf S., Zhu J.Fuentes:googlescopusRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
ArticleAbstract: Background: Direct oral anticoagulants are administered in fixed doses irrespective of body weight,Palabras claves:Cardiovascular Risk, DOAC, prevention, rivaroxabanAutores:Berkowitz S.D., Bhatt D.L., Dyal L., Eikelboom J.W., Fox K.A.A., Guzik T.J., Muehlhofer E., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Ramasundarahettige C., Yusuf S.Fuentes:googlescopus